P D Miller

Summary

Publications

  1. Miller P, Delmas P, Lindsay R, Watts N, Luckey M, Adachi J, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93:3785-93 pubmed publisher
    ..45). Teriparatide was well tolerated. This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure. ..
  2. Miller P, Derman R. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. Osteoporos Int. 2010;21:1793-802 pubmed publisher
    ..Because no single agent is appropriate for all patients, treatment decisions should be made on an individual basis, taking into account the relative benefits and risks in different patient populations. ..
  3. Miller P, Recker R, Reginster J, Riis B, Czerwinski E, Masanauskaite D, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int. 2012;23:1747-56 pubmed publisher
    ..There were no tolerability concerns or new safety signals. Monthly treatment with ibandronate 100 and 150 mg is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis. ..
  4. Miller P. The history of bone densitometry. Bone. 2017;104:4-6 pubmed publisher
    ..The positive impact that ISCD has led in the proper performance and clinical interpretation of bone mass measurements has been enormous worldwide. ..
  5. Miller P, Wagman R, Peacock M, Lewiecki E, Bolognese M, Weinstein R, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011;96:394-402 pubmed publisher
    ..The safety profile of denosumab did not change over time. In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass. ..
  6. request reprint
    Miller P. Bone mass measurements. Clin Geriatr Med. 2003;19:281-97, vi pubmed
    ....

Locale

Collaborators

Detail Information

Publications6

  1. Miller P, Delmas P, Lindsay R, Watts N, Luckey M, Adachi J, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93:3785-93 pubmed publisher
    ..45). Teriparatide was well tolerated. This nonrandomized but prospective study suggests that there may be differences in anabolic responsiveness to teriparatide as a function of the type of prior bisphosphonate exposure. ..
  2. Miller P, Derman R. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. Osteoporos Int. 2010;21:1793-802 pubmed publisher
    ..Because no single agent is appropriate for all patients, treatment decisions should be made on an individual basis, taking into account the relative benefits and risks in different patient populations. ..
  3. Miller P, Recker R, Reginster J, Riis B, Czerwinski E, Masanauskaite D, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int. 2012;23:1747-56 pubmed publisher
    ..There were no tolerability concerns or new safety signals. Monthly treatment with ibandronate 100 and 150 mg is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis. ..
  4. Miller P. The history of bone densitometry. Bone. 2017;104:4-6 pubmed publisher
    ..The positive impact that ISCD has led in the proper performance and clinical interpretation of bone mass measurements has been enormous worldwide. ..
  5. Miller P, Wagman R, Peacock M, Lewiecki E, Bolognese M, Weinstein R, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011;96:394-402 pubmed publisher
    ..The safety profile of denosumab did not change over time. In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass. ..
  6. request reprint
    Miller P. Bone mass measurements. Clin Geriatr Med. 2003;19:281-97, vi pubmed
    ....